Avoro Capital Advisors’s Trillium Therapeutics Inc. TRIL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-5,700,000
| Closed | -$100M | – | 50 |
|
|
2021
Q3 | $100M | Hold |
5,700,000
| – | – | 1.57% | 17 |
|
|
2021
Q2 | $55.3M | Hold |
5,700,000
| – | – | 0.96% | 24 |
|
|
2021
Q1 | $61.2M | Sell |
5,700,000
-100,000
| -2% | -$1.24M | 1.06% | 21 |
|
|
2020
Q4 | $85.3M | Buy |
5,800,000
+300,000
| +5% | +$4.33M | 1.47% | 18 |
|
|
2020
Q3 | $78.2M | Buy |
5,500,000
+750,000
| +16% | +$7.48M | 1.11% | 20 |
|
|
2020
Q2 | $38.4M | Sell |
4,750,000
-200,000
| -4% | -$1.24M | 0.76% | 26 |
|
|
2020
Q1 | $20M | Buy |
+4,950,000
| New | +$18.7M | 0.68% | 29 |
|
|
2017
Q2 | – | Sell |
-227,399
| Closed | -$1.4M | – | 53 |
|
|
2017
Q1 | $1.4M | Hold |
227,399
| – | – | 0.18% | 40 |
|
|
2016
Q4 | $1.28M | Sell |
227,399
-88,621
| -28% | -$882K | 0.26% | 35 |
|
|
2016
Q3 | $4.67M | Buy |
316,020
+87,323
| +38% | +$1.01M | 0.82% | 28 |
|
|
2016
Q2 | $2.05M | Hold |
228,697
| – | – | 0.46% | 29 |
|
|
2016
Q1 | $2.12M | Sell |
228,697
-25,000
| -10% | -$211K | 0.74% | 26 |
|
|
2015
Q4 | $3.2M | Sell |
253,697
-1,400
| -0.5% | -$19.5K | 1.1% | 22 |
|
|
2015
Q3 | $3.35M | Buy |
255,097
+160,697
| +170% | +$2.95M | 0.87% | 23 |
|
|
2015
Q2 | $2.06M | Sell |
94,400
-66,297
| -41% | -$1.51M | 0.57% | 26 |
|
|
2015
Q1 | $3.23M | Buy |
+160,697
| New | +$2.37M | 1.24% | 21 |
|
Other funds holding TRIL
Avoro Capital Advisors's TRIL Position: Q4 2021 in Review
Avoro Capital Advisors sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 5,700,000 shares — an estimated $100M sold.
Avoro Capital Advisors first reported a position in TRIL in Q1 2015 and held it in 16 quarters. The position peaked at $100M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.
- Avoro Capital Advisors reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
- Avoro Capital Advisors sold 5,700,000 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $100M.
- Avoro Capital Advisors first reported a position in Trillium Therapeutics Inc. in Q1 2015 and held it in 16 quarters.
- Avoro Capital Advisors's Trillium Therapeutics Inc. position peaked at $100M in Q3 2021.
- 2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.
Based on Avoro Capital Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.